Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases
Open Access
- 30 November 2009
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis & Rheumatism
- Vol. 60 (12), 3761-3765
- https://doi.org/10.1002/art.24966
Abstract
Objective Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, central nervous system demyelinating disease that results from reactivation of the JC virus, which generally occurs in immunosuppressed hosts. The aim of this study was to generate a national estimate of the frequency of PML among patients with rheumatic diseases. Methods Data were obtained from the Nationwide Inpatient Sample database. This is a 20% sample of all hospital discharges, weighted to represent the entire US inpatient population. Data were analyzed for the years 1998–2005 inclusive, representing 297,797,180 hospital discharges. Cases of PML, systemic lupus erythematosus (SLE), and other rheumatic diseases were identified by diagnostic codes from the International Classification of Diseases, Ninth Revision, Clinical Modification. Results A total of 9,675 cases of PML were identified. The majority were associated with human immunodeficiency virus (HIV; 7,934 patients [82.00%]), hematologic cancers (813 patients [8.40%]), and solid cancers (274 patients [2.83%]). Among the rheumatic diseases, 43 cases of PML (0.44%) were associated with SLE, 24 (0.25%) with rheumatoid arthritis (RA), and 25 (0.26%) with other connective tissue diseases (CTDs). When patients with other potential risk factors for PML (HIV, malignancy, bone marrow or other organ transplantation) were excluded, the rates of PML per 100,000 discharges coded for SLE, RA, and other CTDs were 4, 0.4 and 2, respectively, compared with a rate of PML in the background population of 0.2/100,000 discharges. Conclusion This study was confined to hospitalized patients with rheumatic diseases, and it was also limited by the lack of information regarding immunosuppressive therapy. Nevertheless, the findings suggest that, although rare overall, PML occurs more commonly in SLE than in other rheumatic diseases.Keywords
This publication has 12 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Progressive multifocal leukoencephalopathy – the importance of early diagnosis illustrated in four casesLupus, 2008
- Progressive multifocal leukoencephalopathy and CD4+ T-lymphocytopenia in a patient with Sjögren syndromeJournal of the Neurological Sciences, 2008
- Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximabRheumatology, 2007
- Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of diseaseArthritis & Rheumatism, 2007
- Progressive multifocal leukoencephalopathy in systemic lupus erythematosusArthritis & Rheumatism, 2007
- Improvement of Progressive Multifocal Leukoencephalopathy After Cidofovir Therapy in a Patient with a Destructive PolyarthritisInfection, 2007
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- BK and JC Viruses in Patients with Systemic Lupus Erythematosus: Prevalent and Persistent BK Viruria, Sequence Stability of the Viral Regulatory Regions, and Nondetectable ViremiaThe Journal of Infectious Diseases, 1999